• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma.

作者信息

Li Zhaoming, Lu Lisha, Zhou Zhiyuan, Xue Weili, Wang Yingjun, Jin Mengyuan, Qiu Yajuan, Sun Wei, Fu Xuefei, Zhang Xudong, Chang Yu, Nan Feifei, Yan Jiaqin, Wang Guannan, Sun Zhenchang, Fu Xiaorui, Li Ling, Li Xin, Wang Xinhua, Wu Jingjing, Zhang Lei, Zhang Mingzhi

机构信息

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Lymphoma Diagnosis and Treatment Centre of Henan Province, Zhengzhou, China.

出版信息

Br J Haematol. 2018 May;181(3):406-410. doi: 10.1111/bjh.14611. Epub 2017 Mar 14.

DOI:10.1111/bjh.14611
PMID:28294301
Abstract
摘要

相似文献

1
Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma.皮下脂膜炎样T细胞淋巴瘤中表观遗传修饰因子及PI3K/AKT/mTOR信号通路的复发性突变
Br J Haematol. 2018 May;181(3):406-410. doi: 10.1111/bjh.14611. Epub 2017 Mar 14.
2
A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.全面的免疫组化和分子方法研究膀胱尿路上皮癌中的 PI3K/AKT/mTOR（磷酸肌醇 3-激酶/v-akt 鼠胸腺瘤病毒致癌基因/雷帕霉素的哺乳动物靶标）通路。
BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.
3
Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.分析黑色素瘤患者的 mTOR 基因突变情况及其对 PI3K-AKT-mTOR 通路抑制剂的敏感性评估。
Clin Cancer Res. 2016 Feb 15;22(4):1018-27. doi: 10.1158/1078-0432.CCR-15-1110. Epub 2015 Oct 21.
4
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.PI3K/AKT/mTOR通路作为卵巢癌的治疗靶点
Gynecol Oncol. 2015 Apr;137(1):173-9. doi: 10.1016/j.ygyno.2015.02.003. Epub 2015 Feb 10.
5
A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly.用于诊断PI3K-AKT-mTOR通路相关巨头畸形的基因与生化分析相结合的方法
BMC Med Genet. 2017 Jan 13;18(1):4. doi: 10.1186/s12881-016-0363-6.
6
PLC and PI3K/Akt/mTOR signalling in disease and cancer.疾病与癌症中的磷脂酶C及磷脂酰肌醇-3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白信号通路
Adv Biol Regul. 2015 Jan;57:10-6. doi: 10.1016/j.jbior.2014.10.004. Epub 2014 Nov 26.
7
Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.默克尔细胞多瘤病毒阳性和阴性癌中Akt/mTOR/4E-BP1信号通路激活及PIK3CA突变的比较
Hum Pathol. 2015 Feb;46(2):210-6. doi: 10.1016/j.humpath.2014.07.025. Epub 2014 Oct 23.
8
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.肺癌中 PI3K/AKT/mTOR 通路的详细免疫组化分析：与 PIK3CA、AKT1、K-RAS 或 PTEN 基因突变状态及临床病理特征的相关性。
Oncol Rep. 2013 Aug;30(2):623-36. doi: 10.3892/or.2013.2512. Epub 2013 May 31.
9
Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination.增殖、存活与代谢：PI3K/AKT/mTOR信号通路在多能性及细胞命运决定中的作用
Development. 2016 Sep 1;143(17):3050-60. doi: 10.1242/dev.137075.
10
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.乳腺癌肝转移中PI3K-AKT-mTOR信号通路激活的富集
Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

引用本文的文献

1
Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma.在复发/难治性皮下脂膜炎样T细胞淋巴瘤的晚期治疗中，无化疗挽救治疗优于传统化疗。
Front Immunol. 2024 Dec 9;15:1476875. doi: 10.3389/fimmu.2024.1476875. eCollection 2024.
2
Genetic profiles and clinical features in subcutaneous panniculitis-like T-cell lymphomas.皮下脂膜炎样 T 细胞淋巴瘤的遗传特征和临床特征。
Cancer Sci. 2024 Nov;115(11):3788-3794. doi: 10.1111/cas.16345. Epub 2024 Sep 17.
3
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
杜韦利昔布联合罗米地辛治疗复发/难治性 T 细胞淋巴瘤：一项 1b/2a 期试验。
Nat Med. 2024 Sep;30(9):2517-2527. doi: 10.1038/s41591-024-03076-6. Epub 2024 Jun 17.
4
An investigation of germline variants of in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population.北美人群皮下脂膜炎样T细胞淋巴瘤及相关病变的种系变异研究。
Haematologica. 2024 Oct 1;109(10):3363-3367. doi: 10.3324/haematol.2023.284738.
5
Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders.结外成熟 T 细胞和 NK 细胞淋巴瘤和淋巴增殖性疾病的生物学和遗传学。
Haematologica. 2023 Dec 1;108(12):3261-3277. doi: 10.3324/haematol.2023.282718.
6
Clonotype pattern in T-cell lymphomas map the cell of origin to immature lymphoid precursors.T 细胞淋巴瘤中的克隆型模式将起源细胞映射到未成熟的淋巴前体。
Blood Adv. 2022 Apr 12;6(7):2334-2345. doi: 10.1182/bloodadvances.2021005884.
7
Maximizing insights from monogenic immune disorders.从单基因免疫疾病中获取最大的见解。
Curr Opin Immunol. 2021 Dec;73:50-57. doi: 10.1016/j.coi.2021.09.008. Epub 2021 Oct 22.
8
Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations.皮下脂膜炎样 T 细胞淋巴瘤的遗传学特征及 HAVCR2 突变的临床病理影响。
Blood Adv. 2021 Oct 26;5(20):3919-3930. doi: 10.1182/bloodadvances.2021004562.
9
Current Progress in Investigating Mature T- and NK-Cell Lymphoma Gene Aberrations by Next-Generation Sequencing (NGS).通过下一代测序（NGS）研究成熟T细胞和NK细胞淋巴瘤基因畸变的当前进展
Cancer Manag Res. 2021 Jul 2;13:5275-5286. doi: 10.2147/CMAR.S299505. eCollection 2021.
10
Complete response to romidepsin as monotherapy in treatment-resistant subcutaneous panniculitis-like T-cell lymphoma.罗米地辛单药治疗难治性皮下脂膜炎样T细胞淋巴瘤取得完全缓解。
JAAD Case Rep. 2020 Oct 7;6(12):1245-1247. doi: 10.1016/j.jdcr.2020.09.018. eCollection 2020 Dec.